One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Latin America Liver Cancer Treatment Market

[ 英語タイトル ] Latin America Liver Cancer Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)


Product Code : MDHC0088934
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 80
Category : Healthcare and Pharmaceuticals
Study Area : Latin America
Report format : PDF
Sales price option (consumption tax not included)
Single User USD3750 / Question Form
5 User USD4250 / Question Form
Enterprise User USD7000 / Question Form
 - Alnylam Pharmaceuticals Inc.
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lilly And Co.
- Merck & Co. Inc.
- Eisai Inc.
- Onyx Pharmaceuticals Inc.
- Pfizer Inc.
- Exelixis Inc.

[Report Description]

The Latin American liver cancer treatment market is expected to register a CAGR of nearly 7.9% during the forecast period. Changes in the current lifestyle of individuals led to the exposure of a large amount of population to the risk factors that contribute to liver cancer. The risk factors include hepatitis (caused by either the hepatitis B or hepatitis C virus), type-2 diabetes, metabolic disorders, excess body weight, alcohol consumption, and tobacco smoking. It has also been observed that liver cancer risk increases substantially with the increase in one’s body mass index (BMI). According to the OECD Obesity Update 2017, obesity levels are particularly high in Latin American countries. For example, in Mexico, 32.4% of males aged 15 years and over are obese as of 2017, and nearly 39% of the population is projected to become obese by 2030. Thus, owing to the above factors, the market is expected to show growth in the near future.

Key Market Trends

Hepatocellular Carcinoma Segment is Expected to Hold a Major Share in the Latin America Liver Cancer Treatment Market

Hepatocellular carcinoma is the most common form of liver cancer, which mostly occurs in people suffering from chronic liver disease, like cirrhosis. Hepatocellular carcinoma is one of the major causes leading to cancer-related deaths, globally. It is observed that the developing countries of the Latin American region have higher incidence rates of hepatocellular carcinoma than the developed countries, due to the disparity in the major risk factors, such as hepatitis C virus (HCV) and hepatitis B virus (HBV) infections, causing hepatocellular carcinoma in those regions. With the increase in the incidence of hepatocellular carcinoma, liver cancer therapeutics is expected to have huge demand. Hence, the rising incidence of cancer and high unmet medical needs are the major factors driving the market in the forecast period.

Competitive Landscape

The Latin American liver cancer treatment market is consolidated, with some major players controlling the major share of the market, especially in the diagnostics space. Liver cancer diagnostics are majorly dependent on high-cost diagnostic imaging modalities, such as MRI, CT, and PET scanners. There are few major players in the global market, and due to the low volume of demand in Latin American countries, the concentration of medical device manufacturers is even lower. In the Latin American therapeutic space, several niche players operate, and various clinical trials are underway. Some of the companies that are currently dominating the market are Bayer AG, Bristol-Myers Squibb Company, Merck & Co., Inc, Eisai Inc., Exelixis Inc., Alnylam Pharmaceuticals Inc., Eli Lilly And Co., Onyx Pharmaceuticals Inc., and Pfizer Inc.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Liver Cancer
4.2.2 Technological Advancements in Treatments by Biopharmaceutical Companies
4.3 Market Restraints
4.3.1 Adverse Effects of Drugs
4.3.2 High Cost
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Hepatocellular Carcinoma
5.1.2 Cholangio Carcinoma
5.1.3 Hepatoblastoma
5.1.4 Other Types
5.2 By Therapy
5.2.1 Targeted Therapy
5.2.2 Radiation Therapy
5.2.3 Immunotherapy
5.2.4 Chemotherapy
5.2.5 Other Therapies
5.3 Geography
5.3.1 Latin America
5.3.1.1 Mexico
5.3.1.2 Brazil
5.3.1.3 Argentina
5.3.1.4 Rest of Latin America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Alnylam Pharmaceuticals Inc.
6.1.2 Bayer AG
6.1.3 Bristol-Myers Squibb Company
6.1.4 Eli Lilly And Co.
6.1.5 Merck & Co. Inc.
6.1.6 Eisai Inc.
6.1.7 Onyx Pharmaceuticals Inc.
6.1.8 Pfizer Inc.
6.1.9 Exelixis Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+